SSGJ-706 clinical trials
Also written SSGJ-706.
How each study uses SSGJ-706 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SSGJ-706 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SSGJ-706
- 3
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Shenyang Sunshine Pharmaceutical Co., LTD. (3) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SSGJ-706.
- Dec 2026A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersPhase 2 · Shenyang Sunshine Pharmaceutical Co., LTD.
- Nov 2027SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung CancerPhase 2 · Shenyang Sunshine Pharmaceutical Co., LTD.
Studies
Open first, then newest update. How each study uses SSGJ-706 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung CancerNot yet recruitingPhase 2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07874984Written as SSGJ-706
- A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) PatientsRecruitingPhase 2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07171606Written as SSGJ-706
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersNot yet recruitingPhase 2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850Written as SSGJ-706+Bevacizumab+XELOX
- Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid TumorsStatus unknownPhase 1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06533605Written as SSGJ-706